5‐aminolaevulinic acid/photo‐dynamic therapy and gefitinib in non‐small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy

I Postiglione, SM Aloj - Cell proliferation, 2013 - Wiley Online Library
Objectives Often, non‐small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …
被引用次数：28 相关文章

5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy

I Postiglione, A Chiaviello, SM Aloj… - Cell …, 2013 - pubmed.ncbi.nlm.nih.gov
Objectives Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …

5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.

I Postiglione, A Chiaviello, SM Aloj, G Palumbo - Cell Proliferation, 2013 - europepmc.org
Objectives Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …
[HTML] nih.gov

[HTML][HTML] 5‐aminolaevulinic acid/photo‐dynamic therapy and gefitinib in non‐small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic …

I Postiglione, A Chiaviello, SM Aloj, G Palumbo - Cell Proliferation, 2013 - ncbi.nlm.nih.gov
Objectives Often, non‐small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …

5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.

I Postiglione, A Chiaviello, SM Aloj… - Cell …, 2013 - search.ebscohost.com
Objectives Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …

5‐aminolaevulinic acid/photo‐dynamic therapy and gefitinib in non‐small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy

I Postiglione, A Chiaviello, SM Aloj, G Palumbo - Cell Proliferation, 2013 - infona.pl
Objectives Often, non‐small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …
[PDF] academia.edu

[PDF][PDF] 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy

I Postiglione, A Chiaviello, SM Aloj, G Palumbo - Cell Proliferation, 2013 - academia.edu
Objectives: Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …

5-aminolaevulinic acid/Photo-Dynamic Therapy and Gefitinib in Non Small Cell Lung Cancer cell lines: a potential strategy to improve Gefitinib therapeutic efficacy

I Postiglione, A Chiaviello, S Aloj, G Palumbo - CELL PROLIFERATION, 2013 - iris.unina.it
OBJECTIVES: Often, non-small cell lung cancers (NSCLC) respond only poorly to the
tyrosine kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor …
[PDF] academia.edu

[PDF][PDF] 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy

I Postiglione, A Chiaviello, SM Aloj, G Palumbo - Cell Proliferation, 2013 - academia.edu
Objectives: Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …